Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0% – Time to Sell?

Novo Nordisk A/S (NYSE:NVO) fell 0% on Tuesday . The company traded as low as $69.00 and last traded at $69.41. 1,612,654 shares were traded during mid-day trading, a decline of 81% from the average session volume of 8,313,432 shares. The stock had previously closed at $69.44.

Analysts Set New Price Targets

A number of equities analysts have commented on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Friday, March 21st. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

The firm has a 50 day moving average of $81.64 and a two-hundred day moving average of $97.47. The company has a market cap of $305.48 billion, a PE ratio of 20.70, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Institutional Trading of Novo Nordisk A/S

Several hedge funds have recently bought and sold shares of the stock. Marotta Asset Management increased its holdings in Novo Nordisk A/S by 3.5% in the 1st quarter. Marotta Asset Management now owns 16,653 shares of the company’s stock worth $1,156,000 after acquiring an additional 565 shares in the last quarter. Marcum Wealth LLC raised its stake in Novo Nordisk A/S by 45.9% during the 1st quarter. Marcum Wealth LLC now owns 5,457 shares of the company’s stock valued at $379,000 after purchasing an additional 1,717 shares during the period. Confluence Investment Management LLC raised its position in shares of Novo Nordisk A/S by 1.9% during the first quarter. Confluence Investment Management LLC now owns 10,465 shares of the company’s stock valued at $727,000 after buying an additional 191 shares during the last quarter. Fire Capital Management LLC purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth $389,000. Finally, Wellington Management Group LLP boosted its position in shares of Novo Nordisk A/S by 135.3% during the fourth quarter. Wellington Management Group LLP now owns 830,435 shares of the company’s stock worth $71,434,000 after acquiring an additional 477,557 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.